Servier Laboratories Servier

Servier is a pharmaceutical company managed by a non-profit foundation. The head office of the company is located in Suren, France. For 2020, Servier is represented in 149 countries, and its staff includes 22 thousand employees around the world.

Being completely independent, the Servier group of companies invests on average 25% of its total income (excluding income from reproduced medicines) in research and development. The company's high growth rate for 2020 is due, among other things, to the search for innovations in five key research areas:

• cardiovascular,
• oncological,
• immunoinflammatory,
• neurodegenerative diseases and
• diabetes mellitus,

as well as activities to create high-quality generic medicines.

In addition to the development of drugs, Servier offers solutions in the field of electronic. health care

Performance indicators

2022: Sales growth of 9.8% to reach €4.876 billion

The international independent pharmaceutical group Servier on February 9, 2023 presented financial indicators for the 2021/22 financial year and summed up the interim results of the company's transformation process.

The consolidated sales volume of Servier Group in the 2021/22 financial year compared to the 2020/21 financial year increased by 9.8% and reached 4.876 billion euros. This result is due to an increase in sales volumes at the global level by 7.6% and currency fluctuations - by 3.2% (+ 140 million euros in 2021-2022 and - 156 million euros in the previous year).

Extract from audited consolidated financial statements
(in accordance with IFRS , as of September 30, 2022)

Complex price pressure had a negative impact on sales growth of 1%, which is equivalent to 45 million euros. In the 2021/22 financial year, sales of original medicines rose 12.5% from the previous year to €3.694 billion. Over the same period, generic sales rose 2.0% to €1.182 billion. Fiscal 2021/22 EBITDA reached €859 million, showing a 34.6% (17.6% of group turnover) increase from 14.4% in the previous financial year. Current operating profit for the 2021/22 financial year increased to €442 million and accounted for 9.1% of the group's sales. These indicators are due to the growth of sales in international markets, control and prioritization of expenses, as well as the favorable impact of exchange rates. Net profit of €192 million (3.9% of the group's turnover), while in the previous financial year a loss of €95 million was recorded.

Servier's turnover outside the European Union amounted to more than half of the group's sales (56%), which is 16% higher than the previous financial year. Such active growth became possible, first of all, thanks to the results of the Servier division in the United States, which was ahead of the branch in China and came out on top with sales of 437 million euros (compared with 255 million euros 2020/21). The increase in indicators by 55% is due to the launch of the medicinal product ivosidenib on the US market in the second half of fiscal year 2021/22. In Japan, in the world's second largest cancer drug market, Servier managed to reach 97 million euros thanks to sales of irinotecan, which has been circulating on this market since June 2020 in the indication of "pancreatic cancer therapy."

The sales volume of original medicines in France amounted to 2.7% of the total sales volume, while 51% of the group's investments were directed to the development of production and research activities in this country. This indicator reflects the obligations undertaken by the Servier Group to promote the development of the French economy.

Sales of original medicines for chronic vein disease, cardiovascular disease and metabolic disorders reached €2.693 billion, representing 55.2% of the group's consolidated sales.

The 2.9% i increase compared to fiscal year 2020/21 was driven by the success of the micronized purified flavonoid fraction (MOFF), a drug intended for the treatment of chronic venous insufficiency. It is sold in more than 100 countries of the world and is the flagship for Servier: its sales are 552 million euros. To meet the growing demand and develop the production of the active ingredient of this drug, from 2021, the Servier group invested 100 million euros in its Oril Industrie plant located in Normandy (France).

In FY 2021/22, the fixed combination of amlodipine + indapamide + perindopril (a three-component drug for the treatment of hypertension) reached sales of EUR 211 million.

Growth in sales of the three most significant original medicines of the group in 2021/22

In total sales, the share of drugs for the treatment of oncological diseases increased: in absolute terms, it reached 848 million euros (+ 35.4% i compared to the previous year), which is 17.4% of the total volume (compared with 13.6% in 2020/21). The key contribution to these indicators was made by the drug ivosidenib, approved in the United States for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma, whose sales in 2021/2022 amounted to 256 million euros.

Other oncological drugs also contributed, including the drug pegaspargase, whose sales amounted to 290 million euros (+ 2.8%), and irinotecan, whose sales in 2021-2022 amounted to 145 million euros (+ 13.7%).

The group devotes more than 50% of its budget to research and development in oncology. The group's investments have created a large portfolio of 38 promising oncology research projects (as of January 2023).

Thanks to systemic investments (more than 20% of the turnover of original drugs) in the development of new drugs, Servier has a portfolio of 43 projects at the clinical development stage, and also simultaneously implements 32 research projects. At the same time, the Servier group is implementing 21 projects in the field of neuropsychiatry and immunoinflammatory diseases.

In 2021/22, sales of generic drugs remained stable compared to the previous financial year and at a fixed exchange rate amounted to 1.182 billion euros (24.2% of the group's total sales). The favourable impact of sales volumes was offset by particularly strong price pressures, in particular with respect to medicinal products of the Biogaran subsidiary ("Biogaran"), as well as the extremely significant use of the protective clause in France.

As of January 2023, the group has a portfolio of more than 1,500 generic drugs used for the treatment of a large range of diseases and sold worldwide by four subsidiaries EGIS ("Aegis") : in Eastern, To Europe PharLab (Farlab) in, Brazil Swipha (Swift) Nigeria in and Biogaran (Biogaran), which operates in the generics market in France.

In general, the indicators of the 2021/22 financial year confirm the achievability of the goals set under the Servier strategy by 2025: to achieve total sales of 6.5 billion euros (1 billion euros in oncology) and EBITDA of 1.3 billion euros (or about 20% of sales) by 2025.

Business in Russia

Main article: Servier Rus

History

2022: Collaboration with Onkodizain to find ways to treat pancreatic cancer

pharmaceutical On October 5, 2022, the independent international company Servier announced that it medicine the French Oncodesign Precision Medicine (OPM) had launched scientific a collaboration with the precision biopharmaceutical company to find therapeutic targets for therapy. ductal pancreatic adenocarcinoma Project received the name "STarT Pancreas."

The three-year agreement between Servier and Oncology includes two stages:

• Creating a collaborative AI analytical platform based on data obtained during the OncoSNIPE clinical trial, as well as identifying new therapeutic targets with its help;
• Experimental validation of selected targets.

According to the terms of the partnership agreement, Servier reserves the right to further develop drugs for each of the selected therapeutic targets, both independently and in partnership with Oncology. Companies (under the OncoSNIPE program) will be jointly responsible for conducting clinical trials, while Servier will bear the costs of clinical trials, and the costs of implementing the program to find new targets of the company will be divided among themselves.

Servier will receive an exclusive international license for targets identified during the program. If Servier does not exercise this option, then exclusive rights to some categories of targets will pass to the ORM.

Under the terms of the agreement, Onkodizain will receive an advance payment of 500 thousand euros, and following the successful completion of the first stage of the project (no later than December 31, 2024) - a second payment in the same amount. Servier will also make interim payments until one or more molecules are approved for clinical research.

We are very pleased that over 25 years between Oncology and Servier, the basis for effective interaction has been created, of which OPM has now become a part. This cooperation is a direct result of our investments that we have been making in artificial intelligence technologies since 2017 as part of the OncoSNIPE project. For OPM, this is a very significant project that not only confirms interest in technological developments made over the past 5 years, but also allows us to further strengthen our platform, as well as replenish and structure the database. At the same time, OPM will be able to retain the rights to certain targets for their further development. We are honored to be able to leverage our AI-driven innovations for the needs of precision medicine, said Dr. Philippe Genne, Executive Director and Founder of Oncology.

We are excited to launch a collaboration with OPM, and I hope together we will contribute to the development of AI-based data analysis solutions, which will help us identify new targets for the treatment of pancreatic ductal adenocarcinoma, a terrible disease that is particularly actively developing in industrialized countries. This partnership is in line with the Group's long-term strategy of taking a leading position in oncology to offer innovative therapeutic solutions for hard-to-treat cancers, noted Dr. Walid S. Kamoun, Servier Director of Research and Development in Oncology.

Pancreatic cancer is considered one of the most difficult to treat malignancies with an unfavorable prognosis. In 2018, in France, pancreatic cancer ranked 9th most common in the structure of cancer among men and 7th among women. About 14 thousand new cases are registered in France every year. This means that every year not only the incidence of this type of cancer is growing, but also the need to find effective therapy.

2021

Sales growth of 4.3% to €4.725 billion

On January 18, 2022, Servier published financial indicators for the 2020/21 financial year (ended September 30, 2021) and presented a strategy for research activities.

In 2020/21, Servier Group showed growth, despite the difficult situation around the world. Through the acquisition of Agios Pharmaceuticals Oncology, we have strengthened our position in oncology, and our strategy in this area is showing stable results: drugs are entering the market, as well as expanding indications for use in previously registered ones, allowing patients with intractable cancers to receive therapy. In addition, Servier maintains a position in the treatment of cardiovascular diseases and metabolic disorders and demonstrates increased sales in the group of drugs for the treatment of chronic vein diseases. The initiated digital transformation of Servier Group further contributes to the active development and growth of indicators. We have also strengthened our presence in key markets, in particular in Japan and the United States, and at the same time consolidated the bulk of research and production activities (including the production of biologics) in France. Despite the fact that most of Servier's original medicines (about 96%) are sold outside France, we strive to contribute to the development of healthcare in this country and in Europe as a whole. stated Olivier Lorot, president of the Servier group

According to the company, Servier Group's sales growth for fiscal year 2020/21 was 4.3% compared to 2019/20 at a fixed exchange rate (+ 0.8% at a real exchange rate) and reached 4.725 billion euros. This is due to an increase in sales in packages by 5.3%, which in monetary terms amounted to 246 million euros. 153 million euros of this amount falls on the share of oncological drugs, of which 69 million euros was an increase due to the acquisition of the oncological division of Agios Pharmaceuticals. In other segments, the volume of sales in packages was negatively affected by the government measures taken in China.

Currency fluctuations (-156 million euros) and pressure on prices (-54 million euros) had a negative impact on the indicators of 2020/21.

The volume of sales of original medicines amounted to 3.306 billion euros, which exceeded the indicators of 2019/20 by 4.8% at a fixed exchange rate and 0.6% at a real exchange rate.

Sales of generic drugs increased by 2.9% at a fixed exchange rate (+ 1.1% at a real exchange rate) compared to 2019/20 and reached 1.419 billion euros. As of January 2022, Servier Group produces more than 1,500 generics used to treat a wide range of diseases. Their production and promotion is carried out by four companies within the Group: Biogaran - the leader in the generic drug market in France, EGIS in Eastern Europe, Pharlab in Brazil and Swipha in Nigeria.

In 2020/21, EBITDA remains stable compared to the previous fiscal year at EUR 625 million (13.2% of the Group's turnover); operating profit of EUR 278 million (5.9% of the Group's turnover) remains unchanged.

The past fiscal year was marked by an important milestone in the implementation of our oncology strategy, namely the acquisition and integration of Agios Pharmaceuticals "oncology division. A significant contribution to the growth of the Group's indicators was made by original drugs for the treatment of oncological diseases (+ 34.9%): a drug for the treatment of acute myeloid leukemia, sold in the USA, and a drug for the treatment of metastatic adenocarcinoma of the pancreas, sold in Japan. Despite the negative impact of currency fluctuations and price pressure in China, which was the result of government reforms, growth was + 4.3% at a fixed exchange rate (+ 0.8% at a real exchange rate) compared to 2019/20. noted Pascal Lemaire, Executive Vice President, Finance, Servier Group

Key indicators (as of September 30, 2021)

The acquisition of Agios Pharmaceuticals "oncology division is an example of the Group's oncology strategy. For the development of this area in the 2020/21 financial year, Servier allocated more than half of the budget for research activities. As a result of significant investments, the company's portfolio has been replenished with seven drugs that are already available for patients in different countries of the world.

Sales of drugs for the treatment of cancer increased by 34.9% to 604 million euros, compared to 448 million euros in 2019/20. This result was possible, firstly, thanks to the drug ivosidenib, registered in the USA for the treatment of acute myeloid leukemia (AML) and transferred to Servier's portfolio as a result of the acquisition of the oncology division of Agios Pharmaceuticals (+ 69 million euros), and secondly, thanks to the liposomal form of irinotecan used to treat metastatic adenocarcinoma of the pancreas, its sales doubled compared to the 2019/20 financial year. Since June 2020, the liposomal form of irinotecan has been implemented by the Servier branch in Japan. In the 2020/21 financial year, Servier's division in Japan increased its turnover by 87.5% (at the real exchange rate) - it reached 90 million euros, compared with 48 million euros in 2019/20.

Sales of drugs for the treatment of cardiovascular diseases and metabolic disorders amounted to 2.067 billion euros (44% of the Group's total sales), which, taking into account the fixed exchange rate, is 3.2% lower (-6.9% at the real exchange rate) than in 2019/20 (2.221 billion euros), in particular, due to a decrease in indicators in China.

Micronized purified flavonoid fraction (MOFF), a drug with efficacy in treating symptoms of venous insufficiency, contributes to the Group's performance. In 2020/21, sales of the drug increased by 13.6% at a fixed exchange rate (7.5% at a real exchange rate) and reached 473 million euros (compared with 440 million euros in 2019/20), which allowed MOFF to take a leading position in the company's line of original drugs. The Group has invested EUR 100 million in upgrading the Oril Industry site in Normandy (Bolbeck) with the aim of doubling the production capacity for the production of the drug substance for this drug product by 2023, which will meet the growing global demand. Processes will be implemented at the upgraded production site, as well as another synthesis method to optimize the efficiency and environmental friendliness of the production of the drug substance.

Servier Group's share of sales outside the European Union remains stable and accounts for more than half of the Group's sales (51%). More than a billion packages of Servier medicines have been sold worldwide.

China still holds a leading position in terms of sales of Servier original medicines, despite a 22.8% decrease in indicators due to government reforms. Sales in 2020/21 were €353 million, compared to €457 million in 2019/20.

Servier's representative office in the United States ranks second in terms of sales among the company's branches with a turnover of 255 million euros and an increase of 31.4% (compared with 194 million euros in 2019/2020). These indicators are due, in particular, to the sales of ivosidenib sold in the US market and included in the Servier portfolio after the acquisition of the oncology division of Agios Pharmaceuticals. The third place is occupied by the company's branch in Russia, whose turnover in the reporting period amounted to 247 million euros.

In accordance with the chosen strategy, Servier is transforming its research activities: we strive to achieve the goal of bringing molecules to the market every three years (focusing on the treatment of cancer), as well as investing in the development of drugs for the treatment of neurodegenerative and autoimmune diseases. Our goal is to develop drugs for those diseases where the need for updated therapies is especially high, as well as to develop drugs that even small groups of patients need. The companies included in the Group allowed us to optimize our portfolio and gain opportunities in the field of oncology. We have at our disposal a biotechnological center of expertise in Denmark, reinforced by our investments in the production of biologics in France, as well as a research center in Boston, USA, which will open in the spring of 2022. The Servier Center for Global Expertise in Drug Development will be the Paris-Saclay Research Institute, which is scheduled to open in 2023. narrated by Claude Bertrand, Executive Vice President, Research Activities, Servier Group

Balanced and promising and portfolio of drugs in development (data at the end of December 2021)

Thanks to systemic investments in the development of drugs (more than 20% of profits from original drugs), Servier has a portfolio of 40 potential drugs in clinical development (including 19 additional molecules) and conducts 36 research projects to search for drugs at the preclinical stage. The company focuses its efforts in areas where the need for therapeutic solutions is especially great: oncology, neurodegenerative and immunoinflammatory diseases.

According to a company representative, Servier's strategy for the treatment of cardiovascular diseases and metabolic disorders is to introduce technologies aimed at developing the drugs that patients need. The development of the oncological direction is one of the key priorities for Servier Group: more than 50% of the budget allocated for research activities is allocated to projects for the development of drugs in the field of oncology, in particular, for the treatment of those diseases where the need for other methods of therapy is especially high. Servier focuses its efforts on finding other treatments for patients with intractable diseases, in particular, malignant neoplasms of the gastrointestinal tract and pancreas, hemoblastoses, and the treatment of oncological diseases in children. In its research in the field of oncology, Servier identifies several main areas: apoptosis (restoration of programmed death of cancer cells), immuno-oncology (development in this area was facilitated by the acquisition of the biotechnology company Symphony (Symphogen) in 2020), and the metabolism of cancer cells (using a technique developed by Agios Pharmaceuticals).

Collaboration with Nymirum to find and develop RNA-modulating drugs for the treatment of neurological diseases

The international independent pharmaceutical group Servier and Nymirum, a pioneer in the development of small molecules targeting RNA, have announced the launch of a joint research project aimed at finding and developing RNA-modulating drugs for the treatment of neurological diseases. This became known on July 14, 2021. Read more here.

Completion of acquisition of Agios Pharmaceuticals Oncology Division

On April 5, 2021, the international pharmaceutical company Servier announced the successful completion of the transaction on the acquisition of the Agios Pharmaceuticals portfolio of oncological drugs - both already released on the market and at the stage of clinical research and development. The deal amounted to about $2 billion, and also involves royalties. Read more here.

Fine of 2.7 million euros for the drug that caused the death of 2 thousand people

At the end of March 2021, a French court fined Servier, one of the country's largest pharmaceutical companies, 2.7 million euros, finding her guilty of deception and manslaughter of about 2,000 people. Servier has been accused of concealing potentially fatal side effects of a sufficiently popular drug for. diabetics Mediator More. here

2020

1.6% sales growth to €4.688 billion

On January 27, 2021, the international independent pharmaceutical company Servier shared with Zdrav.Expert the results of its activities for the 2019/20 financial year ended September 30, 2020, and presented a strategy for research and development activities.

Sales of Servier Group in the 2019/20 financial year amounted to 4.688 billion euros, which exceeded the indicators of the 2018/19 financial year by 1.6% at the real exchange rate and 3.6% at the fixed exchange rate. The share of original medicines in the company's sales was 70% (3.285 billion euros), and generics - 30% (1.403 billion euros).

In comparison with 2018/19, the volume of sales of original medicines "Servier" increased by 1.6% at the real exchange rate and by 3.6% at the fixed exchange rate. This growth is mainly due to the increase in sales in packages (by + 2.9%) and the dynamic development of the oncology portfolio.

At the end of the year, operating profit grew to EUR 280 million (6% of total sales), while EBITDA (profit before taxes, interest, depreciation and amortization) amounted to EUR 626 million (13% of total sales), exceeding last year's figures. This was achieved by optimizing costs and re-prioritizing some projects in the context of the coronavirus pandemic.

In addition, during the year, exchange rates had a significant negative impact on sales (-91 million euros), which was more significant compared to the last financial year (-22 million euros), Servier noted.

"In the context of the global health crisis caused by the COVID-19 pandemic, Servier was able to quickly adapt the production and supply processes of its medicines and ensure their availability to patients, while continuing to fully take care of the health and safety of its employees. The results of the fiscal year 2019/20 are in line with the objectives set. Sales of both original drugs and generics contributed to the growth in indicators. The increase in original drug sales was largely driven by advances in oncology, including drugs for acute lymphoblastic leukemia and pancreatic cancer, validating Servier's ambitions to be a key player in this therapeutic field, "said Pascal Lemaire, executive vice president of finance for Servier.

The development of the oncological direction is one of the key priorities for the Servier group: from the 2020/21 financial year, the company plans to allocate 50% of the budget for research and development annually for these purposes. The goal of the group is to become a recognized player in those areas of oncology in which there is a high need for innovation.

Sales of original medicines for the treatment of cancer increased from 397 million euros in 2018/19 to 448 million euros in 2019/20 (an increase of 12.8%). This dynamics is primarily due to high sales rates of drugs for the treatment of acute lymphoblastic leukemia (+ 35.4%), pancreatic cancer (+ 12.7%) and metastatic colorectal cancer (+ 8.9%).

In June 2020, Servier's representative office in Japan received approval for the production and sale of a drug for the treatment of metastatic pancreatic cancer, which, according to the company, led to a significant increase in indicators: 48 million euros in 2019/20 (+ 65% compared to 29 million euros in 2018/19).

Sales of original drugs intended for the treatment of cardiovascular diseases and metabolic disorders amounted to 2.671 billion euros (57% of the group's total sales), which is 2.1% higher than in 2018/19 (2.617 billion euros).

Sales of generic drugs accounted for 30% of the total sales of the Servier group - 1.403 billion euros, with an increase of 1.4% at the real exchange rate and 3.6% at the fixed exchange rate compared to 2018/19. (1.383 billion euros). Four companies in the group produce and promote generic drugs: Biogaran in France, EGIS in Eastern Europe, Pharlab in Brazil and Swipha in Nigeria. For the second year in a row, Biogaran remains the leader in the generic market in France with a 30% market share, according to the group. In general, as of January 2021, Servier produces more than 1,500 generics used to treat a wide range of diseases.

Sales outside France account for 79% of total sales (€3.698 billion), an increase of 3.3% from 2018/19. Most of the original medicines (96%) are also sold outside France.

More than half of the group's sales are in countries outside the European Union, an increase in this indicator of 4.9% compared to 2018/2019.

The leading positions in terms of sales are held by Servier branches in China (sales volume - 457 million euros (+ 3.8%)) and in Russia (sales volume 380 million euros (+ 1.0%)), which consistently demonstrate significant growth potential. The Group's branch, USA Servier Pharmaceuticals, in just two years of its operation was among the top three branches of the group selling original medicines with sales of 194 million euros, which is 7.8% more than in 2018/19 (180 million euros).

During the 2019/20 financial year, Servier Group sold more than one billion packages of medicines worldwide, with 9 out of 10 packages of original drugs sold outside France.

Servier Group seeks to maintain the bulk of its research activities in France, as well as a significant share of its production facilities. Thus, the Oril Industry site in Normandy (Bolbeck) makes a significant contribution to ensuring the independence of the system: health care Europe 98% of Servier's original pharmaceutical drug substances are produced in. To Europe The Group plans to invest an additional 100 million euros in doubling production capacity for the production of the drug substance for the treatment of chronic vein diseases, which will satisfy the growing global demand with less environmental impact.

Another significant component of Servier's industrial strategy in France will be the creation of a biologics division, which will begin its work in 2023 at the Gidy industrial site in the Loire department, France. The Servier Research Institute under construction, investments in the creation of which amount to more than 370 million euros, will be located in the heart most scientific and technical innovation cluster, Sakle Paris.

To improve its performance and expand its investment in therapeutic progress for the benefit of patients, Servier sets itself a number of strategic objectives until 2025. The Group aims to achieve total (consolidated) sales of €6.5 billion by 2025 (€1 billion in oncology), EBITDA of €1.3 billion and launch a new molecule every three years (at least one to be launched by 2025).

To achieve its goals, the Group accelerates the transformation process in all areas and areas of its activities, including in the field of digital technologies, which are an important component of the development and efficiency of the group: for this purpose, a division of digital data and information systems was created.

Servier Group has ambitious targets until 2025 aimed at improving its current performance in order to develop new drugs for the benefit of patients. That is why we are accelerating the global transformation of the group in all its business segments. This is necessary in order to further promote therapeutic progress, to guarantee the sustainability of our work and our independence, "said Olivier Loro, president of Servier.

The transformation of the Servier Group's research and development approach is based on three components: a patient-oriented approach based on translational medicine, a more effective organizational structure and effective cooperation, and a reorientation of activities to three main areas of expertise.

To achieve success in creating therapeutic innovations while maintaining the distinctive features that made their development possible, Servier decided to focus its efforts on three key therapeutic areas: in oncology, the goal is to focus on intractable forms of cancer, and in the field of immunoinflammatory and neurodegenerative diseases, work will be aimed at those pathologies whose therapeutic need remains unmet.

A research model focused on the therapy of neurological and immunoinflammatory diseases led to the decision to suspend research activities in the field of cardiology and metabolic disorders. The focus will now be on innovations in drug lifecycle management for the treatment of cardiovascular disease and metabolic disorders (LCM, Life Cycle Management).

"To achieve the Group's goals, an action plan focused on denovo innovation was developed by 2025, that is, accelerating the development of new drugs to meet therapeutic needs in the fields of oncology, neurology and immunoinflammatory diseases. The plan is based on innovations in drug lifecycle management by increasing the scope of research, in particular with regard to drugs for the treatment of cardiovascular diseases and metabolic disorders. The transformation project will be implemented thanks to the engagement and flexibility of our teams, "said Claude Bertrand, Executive Vice President, Research and Development, Servier Group.

The de novo approach makes it possible to place a special emphasis on oncology research, which will account for about 50% of Servier's total investment in research and development in the 2020/21 financial year. The goal of the approach is to create a portfolio of targeted, based on the search for biomarkers, drugs for the treatment of solid tumors, as well as to continue the search in the field of oncohematology. This approach is also aimed at balancing the portfolio by including drugs with new mechanisms of action - monoclonal antibodies and small molecules. In the long term, the company is faced with the task of forming an innovative portfolio of drugs for the treatment of intractable oncological diseases, such as cancers of the liver, pancreas and certain types of neoplasms in children.

The denovo approach will also allow investment in promising projects in the treatment of neurodegenerative and immunoinflammatory diseases in target groups of patients. The transformation plan of the research and development division also involves the use of digital technologies, which can be a serious challenge, in particular, in relation to data processing and access to them, according to the group. Specialized programs in this area will strengthen the dynamics of cooperation and achieve greater efficiency and productivity.

Thanks to significant and constant investments in research and development (23% of the turnover of original drugs) for January 2021, Servier has a portfolio of 27 potential drugs in clinical development (including 16 new molecules) and is conducting 33 research projects to find new drugs. The group operates within 30 alliances under 40 research agreements.

"The growth the company is experiencing at the end of the 2019/20 financial year is in line with the targets set and reflects our commitment to therapeutic progress for the benefit of patients. Thanks to systemic investments in research and development, we have a significant portfolio of potential drugs in those therapeutic areas where there is a high need for innovation. The crisis facing the health care system has further strengthened our commitment to supporting Europe's medicinal independence. France, along with the expansion of its global presence, remains a priority for Servier Group, whose drugs are used daily by more than 100 million patients in 150 countries of the world, "said Olivier Lorot, President of Servier.

Acquisition of Agios Pharmaceuticals Cancer Division

The international pharmaceutical company Servier has entered into an agreement to acquire the oncology division of Agios Pharmaceuticals. This became known on December 23, 2020. Read more here.

Purchase of biotech company Symphogen

In June 2020, the Servier group bought the Symphogen biotechnology company. This deal allowed Servier to strengthen its portfolio of oncological drugs. Symphogen became the group's centre of excellence for antibody development, and in just six months of operation (by December 2020) presented two research projects.

Opening in partnership with Centech of the international "Center for Artificial Intelligence" in Montreal

On December 15, 2020, the international pharmaceutical company Servier announced the opening of the Center for Artificial Intelligence in Montreal, the partner was Centech. Read more here.

Agreement with the Autonomous University of Barcelona to accelerate research on Parkinson's disease

On July 8, 2020, it became known that the international independent pharmaceutical company Servier and the Autonomous University of Barcelona (Autonomous University of Barcelona) signed a cooperation agreement to accelerate research on Parkinson's disease using a small molecule screening method. Read more here.

2019: Sales amounted to €4.615 billion

On February 20, 2020, the independent international pharmaceutical company Servier published sales figures for the 2018/19 financial year and presented an overview of research activities. Servier Group's sales in the 2018/19 financial year amounted to €4.615 billion, which exceeded last year's figures by 10.5%. In percentage terms, 70% of consolidated sales (3.232 billion euros) accounted for sales of original medicines, and 30% (1.383 billion euros) ─ for sales of generics. Operating profit decreased by 34.2%, to 202 million euros, which, in particular, was influenced by the purchase of new drugs for the treatment of acute lymphoblastic leukemia and for the treatment of pancreatic cancer, as well as investments in the opening of the Servier branch in Boston, USA. Also, during the financial year, exchange rates had a smaller impact on sales (- 22 million euros) compared to the previous year (- 160 million euros).

" The 2018/19 financial year results exceeded targets. The increase in our results was driven by increased sales of original drugs, especially in China, Russia and Brazil, and in oncology ─ sales of the drug for the treatment of acute lymphoblastic leukemia, in particular in the United States. A 7.5% increase in generic sales also contributed substantially to our growth, " noted Dominique Brissy, Senior Executive Vice President, Finance and Information Systems, Servier Group

In 2018/19, sales of original medicines amounted to 3.232 billion euros, showing an increase of 11.8%. This was made possible by an increase in sales in packages by 4.4%, which made it possible to compensate for the losses from fluctuations in drug prices and the expiration of a number of patents.

According to the company, Servier continues to occupy a leading position in the treatment of cardiovascular diseases with sales of 2.4 billion euros (53% of the Group's total sales) and ranked 2nd in Europe and 6th in the world. Servier plans to continue to develop steadily in this direction, in particular, pinning serious hopes on the drug myosin activator for the treatment of CHF, which is in the third phase of clinical trials as of March 2020, as well as on new fixed combinations.

The Group's sales in the field of oncology (EUR 578 million) increased by 120% due to sales of two original drugs ─ for the treatment of acute lymphoblastic leukemia and for the treatment of pancreatic cancer, as well as increased sales of biosimilars. The drug for colorectal and gastric cancer also showed a significant increase of + 15.5%.

In 2019, the Group took several important steps: a new indication for colorectal and gastric cancer was registered in Europe, a drug for the treatment of acute lymphoblastic leukemia was launched in the United States, and drug rights were acquired for the treatment of repeatedly recurrent or treatment-resistant aggressive non-Hodgkin B-cell lymphomas around the world.

Generics are manufactured by four divisions of the Group in France, Eastern Europe, Brazil and Nigeria. As of March 2020, Servier Group has 1,500 generics in its portfolio for the treatment of a wide range of diseases. Sales of generic drugs amounted to 1.383 billion euros. With an increase of 7.5% in ─, this area of ​ ​ the company continues to develop dynamically and diversify, in particular, in the field of over-the-counter drugs and biosimilars.

In 2018/19, biosimilar sales increased by 42%, 11.8% of which were sales of Biogaran drugs in France. Biogaran launched 59 drugs in 2018/19.

The Group's sales in international markets reached EUR 3.580 billion, representing 78% of consolidated sales. At the same time, in 11 countries, where more than half are in the EU countries, sales amounted to more than 100 million euros. The first and second places in terms of sales are occupied by Servier Group branches in China (440 million euros, 20% growth) and Russia (376 million euros, 6% growth), respectively, which continue to demonstrate great growth potential. The company's US branch was the 4th largest company in terms of sales and marked its first year of operation. As of March 2020, 9 out of 10 packages of original Servier medicines are sold outside France.

As noted in Servier, the Group has a promising development portfolio ─ 30 candidate drugs and 32 research projects. As of March 2020, there are two molecules in a phase III clinical trial:

• Myosin activator, development as part of a collaboration between Amgen and Cytokinetics with financial and strategic support from Servier.
• Loop diuretic, co-development with Neurochlore.

To meet the needs of patients for new therapeutic solutions, Servier Group has seriously revised its strategy, placing a significant emphasis on oncology research. To do this, the Group supports and develops research programs and projects, expands the number of partnership agreements, and actively invests in research and development in this area. Thus, in 2018/19, investments in the oncological direction amounted to 36% of the research budget, with a growth potential of up to 50%. This approach has led to the emergence of six new drugs, 12 candidate drugs at the clinical research stage, 17 partner research projects, primarily focused on therapy to restore programmed cancer cell death (apoptosis) and activation of the immune system (immuno-oncology), is under implementation.

The Group remains fully committed to the Corporate Social Responsibility (CSR) strategy, in particular, with the goal of minimizing CO2 emissions by 25% by 2030.

2016: 20,000 employees in 140 countries

According to 2016 information, Servier is represented in 140 countries on 5 continents, the company employs more than 20,000 employees worldwide, including 3,000 scientists developing new drugs.

1954: Founding of the Company

Founded in 1954, Servier became the first independent the French pharmaceutical company.